




Searching News Database: Ortho-McNeil
HSMN NewsFeed - 5 May 2014
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
HSMN NewsFeed - 24 Jun 2013
Exalenz Bioscience Names Ted Foltyn New VP of Worldwide Marketing and Business Development
Exalenz Bioscience Names Ted Foltyn New VP of Worldwide Marketing and Business Development
HSMN NewsFeed - 5 Dec 2012
Savient Announces the Election of Robert G. Savage to its Board of Directors
Savient Announces the Election of Robert G. Savage to its Board of Directors
HSMN NewsFeed - 10 May 2012
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer
HSMN NewsFeed - 14 Jan 2011
Orexo and Invida Jointly Announce Agreement for Abstral(TM) in Asia Pacific
Orexo and Invida Jointly Announce Agreement for Abstral(TM) in Asia Pacific
HSMN NewsFeed - 10 Jan 2011
Orexo: FDA Approval For Abstral (Fentanyl) Sublingual Tablets - US Launch Planned For Q1 2011
Orexo: FDA Approval For Abstral (Fentanyl) Sublingual Tablets - US Launch Planned For Q1 2011
HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
HSMN NewsFeed - 14 Sep 2009
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 2 Apr 2009
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
HSMN NewsFeed - 27 Mar 2009
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
HSMN NewsFeed - 23 Mar 2009
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
HSMN NewsFeed - 31 Dec 2008
PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
HSMN NewsFeed - 16 Dec 2008
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
HSMN NewsFeed - 24 Jul 2008
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
HSMN NewsFeed - 14 Jul 2008
Noven Names Joel Lippman, M.D. as Vice President - Clinical Development & Chief Medical Officer
Noven Names Joel Lippman, M.D. as Vice President - Clinical Development & Chief Medical Officer
HSMN NewsFeed - 18 Apr 2008
Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
HSMN NewsFeed - 2 Jan 2008
Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol
Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 3 Oct 2007
Postoperative Pain is an Under Appreciated, Under Treated Problem in the United States
Postoperative Pain is an Under Appreciated, Under Treated Problem in the United States
HSMN NewsFeed - 2 Oct 2007
Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
HSMN NewsFeed - 7 Aug 2007
NeurAxon Appoints Robert Medve, M.D., as Chief Medical and Regulatory Officer
NeurAxon Appoints Robert Medve, M.D., as Chief Medical and Regulatory Officer
HSMN NewsFeed - 19 Jul 2007
Ortho-McNeil, Inc. Settles Patent Infringement Litigation Against Par/Kali
Ortho-McNeil, Inc. Settles Patent Infringement Litigation Against Par/Kali
HSMN NewsFeed - 19 Jul 2007
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet(R) Patent Litigation
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet(R) Patent Litigation
HSMN NewsFeed - 7 Jun 2007
Patrick Gallagher Joins Acusphere as Senior Vice President, Business Development
Patrick Gallagher Joins Acusphere as Senior Vice President, Business Development
HSMN NewsFeed - 18 May 2007
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
HSMN NewsFeed - 9 May 2007
Data Show Low Incidence of Breakthrough Bleeding With ORTHO TRI-CYCLEN(R) LO In a Broad Range of Women
Data Show Low Incidence of Breakthrough Bleeding With ORTHO TRI-CYCLEN(R) LO In a Broad Range of Women
HSMN NewsFeed - 3 May 2007
Metabolex Names Charpentier to the Post of Vice President for Regulatory Affairs
Metabolex Names Charpentier to the Post of Vice President for Regulatory Affairs
HSMN NewsFeed - 10 Nov 2006
Mylan Receives Final FDA Approval for Oxybutynin Chloride Extended-release Tablets
Mylan Receives Final FDA Approval for Oxybutynin Chloride Extended-release Tablets
HSMN NewsFeed - 25 Sep 2006
Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists
Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists
HSMN NewsFeed - 12 Sep 2006
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
HSMN NewsFeed - 7 Sep 2006
U.S. Court of Appeals Rules in Favor of Mylan in Oxybutynin Patent Litigation
U.S. Court of Appeals Rules in Favor of Mylan in Oxybutynin Patent Litigation
HSMN NewsFeed - 23 May 2006
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
Additional items found! 102

Members Archive contains
102 additional stories matching:
Ortho-McNeil
(Password required)
Ortho-McNeil
(Password required)